CD8A and glycogen storage disease VI: However, the usefulness of alemtuzumab in this case and similar reports of perivascular and parenchymal CD3+ and CD8+ T lymphocytes in IgLON5-IgG disease autopsy specimens may contradict this view and support the consideration of a more personalised approach to diagnosis and treatment of rare diseases such as IgLON5-IgG disease [15,42].